Nemours Children’s Health selected to conduct first gene therapy for Morquio A syndrome
May 17, 2023Research and Development Morquio A syndrome, NIH, Nemours Children's Health, Paediatrics, gene therapy
Nemours Children’s Health, based in Delaware, US, has been chosen by the Foundation for the National Institutes of Health (FNIH) …
AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
May 17, 2023Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy
AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …
NICE recommends nine digital treatment options for depression and anxiety
May 17, 2023Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health
The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …
FDA grants Priority Review for Takeda’s cTTP treatment
May 17, 2023Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP
Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …
RadioMedix and Orano Med complete patient enrolment for neuroendocrine cancer trial
May 16, 2023Medical Communications Oncology, Orano Med, RadioMedix, neuroendocrine cancer, oncology
US-based RadioMedix and French Orano Med, two clinical stage radiopharmaceutical companies, have announced that the last patient has been enrolled …
Nido Biosciences raises $109m in funding for neurological diseases treatments
May 16, 2023Sales and Marketing Financing, Neurology, Nido Biosciences, funding, neurology
US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series A and Series B financings, …
Astellas and Sony enter collaborative research agreement
May 16, 2023Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement
Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …
uniQure announces sale of royalty interest in Hemgenix for up to $400m
May 16, 2023Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure
uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …
LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC
May 15, 2023Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology
Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …
Relief Therapeutics awarded approval from Swissmedic for new GMP-compliant laboratory
May 15, 2023Research and Development GMP, Relief Therapeutics, Swissmedic, laboratory
Swiss biopharmaceutical company Relief Therapeutics has announced that its state-of-the-art R&D laboratory in Balerna, Switzerland, has been audited and approved …
NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis
May 15, 2023Medical Communications NHS, NICE, Virology, hepatitis
The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …
FDA approves new nonhormonal medication for menopause hot flashes
May 15, 2023Medical Communications FDA, HRT, Veozah, hot flashes, menopause
The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an oral medication to treat moderate …
FDA relaxes blood donation regulations for MSM
May 12, 2023Medical Communications FDA, HIV, HIV/AIDS, blood donation
The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …
Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies
May 12, 2023Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy
Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …
Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug
May 12, 2023Medical Communications Bellerophon Therapeutics, Cardiology, clinical trial, lung disease
US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed its phase 3 REBUILD study, …
FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment
May 12, 2023Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy
US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …
FDA advisory committee votes in favour of OTC contraceptive pill
May 11, 2023Medical Communications Contraception, FDA, OTC, Perrigo, contraception
Perrigo Company has announced that the US Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, …
Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug
May 11, 2023Medical Communications FDA, Lundbeck, Neurology, Otsuka Pharmaceuticals, alzheimer's disease, dementia
Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US Food and Drug Administration (FDA) …
AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD
May 11, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology
AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …
FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy
May 11, 2023Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy
The US Food and Drug Administration (FDA) has released a report in preparation for its 12 May decision on Sarepta …
Latest content
FibroFind appoints Lee Borthwick as CEO
